WEI HU to Angiogenesis Inhibitors
This is a "connection" page, showing publications WEI HU has written about Angiogenesis Inhibitors.
Connection Strength
0.219
-
New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65.
Score: 0.072
-
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9.
Score: 0.058
-
Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006 Jun; 6(4):333-63.
Score: 0.040
-
Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):701-34.
Score: 0.033
-
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
Score: 0.016